Diamyd Medical Valuation
| DMN Stock | EUR 0.99 0.04 4.21% |
Today, the firm appears to be overvalued. Diamyd Medical AB shows a prevailing Real Value of €0.89 per share. The current price of the firm is €0.99. Our model computes the value of Diamyd Medical AB from reviewing the firm fundamentals such as Shares Owned By Insiders of 35.22 %, current valuation of 96.81 M, and Shares Outstanding of 76.93 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Diamyd Medical's price fluctuation is dangerous at this time. Calculation of the real value of Diamyd Medical AB is based on 3 months time horizon. Increasing Diamyd Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Diamyd stock is determined by what a typical buyer is willing to pay for full or partial control of Diamyd Medical AB. Since Diamyd Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Diamyd Stock. However, Diamyd Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.99 | Real 0.89 | Hype 0.99 |
The real value of Diamyd Stock, also known as its intrinsic value, is the underlying worth of Diamyd Medical AB Company, which is reflected in its stock price. It is based on Diamyd Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Diamyd Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Diamyd Medical AB helps investors to forecast how Diamyd stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Diamyd Medical more accurately as focusing exclusively on Diamyd Medical's fundamentals will not take into account other important factors: Diamyd Medical Total Value Analysis
Diamyd Medical AB is currently estimated to have takeover price of 96.81 M with market capitalization of 99.6 M, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Diamyd Medical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
96.81 M | 99.6 M |
Diamyd Medical Investor Information
About 35.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.11. Diamyd Medical AB had not issued any dividends in recent years. Based on the analysis of Diamyd Medical's profitability, liquidity, and operating efficiency, Diamyd Medical AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Diamyd Medical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Diamyd Medical has an asset utilization ratio of 0.19 percent. This implies that the Company is making €0.001919 for each dollar of assets. An increasing asset utilization means that Diamyd Medical AB is more efficient with each dollar of assets it utilizes for everyday operations.Diamyd Medical Ownership Allocation
Diamyd Medical holds a total of 76.93 Million outstanding shares. Diamyd Medical AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Diamyd Medical Profitability Analysis
The company reported the revenue of 454 K. Net Loss for the year was (103.52 M) with loss before overhead, payroll, taxes, and interest of (3.95 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Diamyd Medical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Diamyd Medical and how it compares across the competition.
About Diamyd Medical Valuation
The stock valuation mechanism determines Diamyd Medical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Diamyd Medical. We calculate exposure to Diamyd Medical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Diamyd Medical's related companies.Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.
8 Steps to conduct Diamyd Medical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Diamyd Medical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Diamyd Medical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Diamyd Medical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Diamyd Medical's revenue streams: Identify Diamyd Medical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Diamyd Medical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Diamyd Medical's growth potential: Evaluate Diamyd Medical's management, business model, and growth potential.
- Determine Diamyd Medical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Diamyd Medical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Diamyd Stock analysis
When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |